Overview
- Aleniglipron produced 16.3% placebo-adjusted weight loss at 44 weeks on 180 mg and 16.0% on 240 mg in ACCESS II, with no sign of plateauing.
- Results compare favorably with competing oral GLP-1s, topping Novo Nordisk’s reported 13.6% and Eli Lilly’s roughly 12.4% in prior trials.
- Extension studies reported low adverse event–related discontinuation rates of about 2% to 3.4%, supported by a low 2.5 mg starting dose strategy.
- Structure plans an end-of-Phase 2 FDA meeting in Q2 2026 and expects to begin Phase 3 in H2 2026, with dose selection guided by the Phase 2 data.
- Shares rose roughly 9%–10% on the readout as the CEO said the company is engaging with potential acquirers or partners, while analysts cautioned that Phase 3 confirmation and a placebo-group anomaly bear watching.